Russia’s Sputnik V Covid-19 vaccine is claimed to be 91.6% effective against Coronavirus. The efficacy is 91.8% for Covid-19 affected people over 60 age.
Such a claim is made on the basis of the analysis of the interim data of the third stage trial.
Earlier, a second interim analysis of the experimental application of the vaccine claimed that it was 95% effective.
More than 20,000 people took part in the Sputnik-V Covid-19 vaccine test, the UK newspaper The Guardian reported today. One-third of them are vaccinated. The rest are given the placebo (unresponsive fluid). None of the original vaccine recipients had any major side effects.
Although some people had mild fever-like symptoms after the vaccination, they felt pain or weakness at the injection site.
According to researchers in the UK medical journal The Lancet, 2,144 people over the age of 60 were vaccinated in the experiment. They had coronavirus symptoms.
In this case, the effectiveness of the Sputnik-V Covid-19 vaccine is found to be 91.6%.
The Sputnik V vaccine is manufactured by the Gamalea Research Center, the Russia Direct Investment Fund (RDIF) and the Russian Ministry of Health. This vaccine is to be taken in two doses at intervals of 21 days.
Stephen Griffin, an associate professor at the School of Medicine at the University of Leeds in the UK, said the results of the third-tier test data analysis were quite encouraging in terms of effectiveness. There are no major side effects and it is equally effective in elderly patients.
Now the final stage of this vaccine test will begin. At this stage, 40,000 volunteers will participate in the examination. However, Russian authorities have previously allowed the vaccine to be used.
Sputnik-V has been applied to the human body to prevent Covid-19 in several countries, including Russia.
In addition, Pfizer-BioNTech, Oxford-AstraZeneca, Moderna and Synoform vaccines have been introduced in different countries.